Compositions and methods to treat cardiac diseases

Patent metadata

Field	Value
Publication number	US-9526739-B2
Application number	US-201615046630-A
Country	US
Kind code	B2
Filing date	Feb 18, 2016
Priority date	Feb 22, 2010
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded.

First claim

The invention claimed is:

1. A method of improving cardiac contractile performance or cardiac function in a mammal in need thereof, comprising administering an effective amount of a phosphonate or phosphinate N-methanocarba derivative of AMP, wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is

wherein
Q 1 is O or S;
R 1 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, halogen, or N(R 6 ) 2 , wherein each R 6 is independently hydrogen, optionally substituted alkyl, or optionally substituted cycloalkyl;
R 2 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkynyl, N(R 6 ) 2 , or halogen;
R 3 is hydrogen, optionally substituted alkyl, N(R 6 ) 2 , or halogen;
R 4 is hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted —Oaryl, or N(R 6 ) 2 ;
R 5 is hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, or optionally substituted —Oaryl; or
alternatively, R 4 and R 5 form a 5- or 6-membered cyclic structure with the phosphorus atom where the cyclic structure contains at least two oxygen atoms attached to the phosphorous atom and at least 2 carbon atoms, wherein the carbon atom or atoms closest to the phosphorous atom are optionally substituted with alkyl or aryl; and
Y is a linking group linked to the phosphorus atom by a carbon atom; or

wherein X is O or S; n is 1, 2, or 3; and R 7 is optionally substituted alkyl or optionally substituted aryl, and wherein variables R 1 -R 3 and Y are the same as above; or

wherein Z is a bond or —O—C(═O)— where the carbonyl carbon is bonded to the oxygen of the bicycle group and the oxygen is bonded to the phosphorus atom, and wherein variables R 1 -R 3 and Y are the same as above; or

wherein R 8 is optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted aryl; and R 9 is methoxy, and wherein variables R 1 -R 3 , R 5 and Y are the same as above; or

wherein G is O or S—S; and R 10 is hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted aryl, and wherein variables R 1 -R 3 and Y are the same as above; or

wherein R 11 is hydrogen, optionally substituted alkyl, or optionally substituted aryl, and wherein variables R 1 -R 3 and Y are the same as above; or

wherein
Q 1 is O or S;
Q 2 is O or S;
Y 1 is a linking group,
variables R 1 -R 5 are the same as above
with the proviso that when Q 1 and Q 2 are both O, and Formula (VII) is not enriched with deuterium, then R 4 and R 5 are not both hydroxyl,
a deuterium enriched isomer thereof, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP of claim 1 is Formula (I) or (VII).

3. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is Formula (I) wherein Q 1 is O; R 1 is N(R 6 ) 2 wherein each R 6 is hydrogen; R 2 is halogen; R 3 is hydrogen; R 4 is hydroxyl or optionally substituted alkoxy; R 5 is hydroxyl or optionally substituted alkoxy; and Y is a linking group linked to the phosphorus atom by a carbon atom.

4. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is Formula (I) wherein Q 1 is O; R 1 is N(R 6 ) 2 wherein each R 6 is hydrogen; R 2 is halogen; R 3 is hydrogen; R 4 is hydroxyl or optionally substituted alkoxy; R 5 is hydroxyl or optionally substituted alkoxy; and Y is a C 1 -C 6 alkylene.

5. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is Formula (VII) wherein Q 1 is O; Q 2 is S; R 1 is N(R 6 ) 2 wherein each R 6 is hydrogen; R 2 is halogen; R 3 is hydrogen; R 4 is hydroxyl or optionally substituted alkoxy; R 5 is hydroxyl or optionally substituted alkoxy; and Y 1 is a C 1 -C 6 alkylene.

6. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is Formula (VII) wherein Q 1 is S; Q 2 is O; R 1 is N(R 6 ) 2 wherein each R 6 is hydrogen; R 2 is halogen; R 3 is hydrogen; R 4 is hydroxyl or optionally substituted alkoxy; R 5 is hydroxyl or optionally substituted alkoxy; and Y 1 is a C 1 -C 6 alkylene.

7. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is

8. The method of claim 1 , wherein the phosphonate or phosphinate N-methanocarba derivative of AMP is

9. The method of claim 1 , wherein the mammal has had or is suspected of having a myocardial infarction.

10. The method of claim 9 , wherein administering is performed within the short-term post-infarction period.

11. The method of claim 1 , wherein the mammal is suffering from heart failure.

12. The method of claim 11 , wherein the heart failure is diastolic heart failure.

13. The method of claim 1 , wherein improved cardiac function is improving the ability of the heart to relax, providing favorable remodeling in a subject with heart failure, decreasing fibrosis, decreasing the hypertrophy of cardiac myocytes, improving calcium handling in myocytes in a heart failure subject, or a combination thereof.

Assignees

• Univ Connecticut
• Us Health
• Us Health

Inventors

• Liang Bruce
• Jacobson Kenneth A

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C07F9/65616

  containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs · CPC title

• A61K31/675 Primary

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title